BeOne Medicines Ltd. (ONC) operating KPIs
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)
Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –
Latest, Q2 2026
30.0%
Period ended Jun 30, 2026
Change on a year earlier
-54.9 pts
84.9% in Q2 2025
History
8 quarters
Since Q1 2024
Sources
8
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | BRUKINSA — Europe Revenue Growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 30.0% | -54.9 pts | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 57.4% | -16.0 pts | Form 10-Q (filed 2026-05-06) ↗ |
| Q3 2025 | Sep 30, 2025 | 67.8% | -149.4 pts | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2025 | Jun 30, 2025 | 84.9% | -124.3 pts | Form 10-Q (filed 2025-08-06) ↗ |
| Q1 2025 | Mar 31, 2025 | 73.4% | -169.4 pts | Form 10-Q (filed 2025-05-07) ↗ |
| Q3 2024 | Sep 30, 2024 | 217.2% | – | Form 10-Q (filed 2024-11-12) ↗ |
| Q2 2024 | Jun 30, 2024 | 209.2% | – | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2024 | Mar 31, 2024 | 242.8% | – | Form 10-Q (filed 2024-05-08) ↗ |
Cite this data
StockData. (2026). BeOne Medicines BRUKINSA — Europe Revenue Growth YoY (%) (%), quarterly Q1 2024–Q2 2026 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/prod_brukinsa_eu_yoy
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.